Allo-THYTECH
Financiado
Development and implementation in clinical practice of the allogeneic use of thy...
Development and implementation in clinical practice of the allogeneic use of thymus derived regulatory T cells thyTreg as a cell therapy to suppress harmful immune responses
Cell therapy based on regulatory T cells (Treg) transfer has acquired great interest for the treatment of autoimmune diseases, graft rejection or graft versus host disease (GVHD). Until now, this therapy has not rendered definitiv...
Cell therapy based on regulatory T cells (Treg) transfer has acquired great interest for the treatment of autoimmune diseases, graft rejection or graft versus host disease (GVHD). Until now, this therapy has not rendered definitive clinical results in humans mainly due to the low number and limited quality of differentiated Treg purified from adult peripheral blood. To overcome these limitations, the host group has developed a new technology to produce massive amounts of GMP Treg derived from the thymic tissue (thyTreg), which are being employed in a clinical trial as an autologous cell therapy in transplanted children. However, the massive amount of thyTreg obtained from each thymus make possible to produce hundreds of doses that could be also employed allogenically to treat a range of immune diseases and patients. My experience and acquired skills in immunology will provide the host with the adequate knowledge to develop the allogenic use of thyTreg. The goal of my research will be to investigate the immunogenicity of thyTreg and confirm that its immature phenotype makes possible its off-the-self use, and secondly to initiate a clinical trial to evaluate the safety/feasibility of a therapy with allogenic thyTreg in patients with GVHD. The project will establish the basis for the development of allogenic thyTreg cell therapies to suppress the harmful immune response underlying autoimmune diseases, transplant rejection, GvHD, and cytokine release syndrome associated with CAR-T therapy or clinical progress in COVID-19 patients. This innovative project will reinforce my expertise in immune disorders, gaining experience in translational research from the pre-clinical stages to the development of clinical trials and transfer of technology. Being part of this host institution participating in leading projects and international partnerships provides the ideal environment to complete my training and to develop my leadership abilities to become an independent researcher.
ver más
Duración del proyecto: 39 meses
Fecha Inicio: 2021-03-24
Fecha Fin: 2024-07-12
Fecha Fin: 2024-07-12
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2024-07-12
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
MSCA-IF-2020:
Individual Fellowships
Cerrada
hace 4 años
Presupuesto
El presupuesto total del proyecto asciende a
173K€
Líder del proyecto
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
3M
Perfil tecnológico
TRL
4-5
3M